Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines (original) (raw)
References
Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Kramer MD, Jänicke F, Klijn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648–1658, 1994 PubMed Google Scholar
Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30: 5–11, 1994 Google Scholar
Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjöld B: The South-East Sweden Breast Cancer Group. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. Int J Cancer 51: 28–33, 1992 PubMed Google Scholar
Alghanem AA, Hussain S: The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer. J Surg Oncol 31: 218–221, 1986 PubMed Google Scholar
Clark GM, McGuire WL: Prognostic factors in primary breast cancer. Breast Cancer Res Treat 3 (Suppl): S69–S72, 1983 PubMed Google Scholar
McGuire WL: Hormone receptor in breast cancer. In: Bulbrook RD (ed) Cancer Surveys. Vol 5. Oxford University Press, Oxford, 1986, pp 527–536 Google Scholar
Garcia M, Derocq D, Freiss G, Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89: 11538–11542, 1992 PubMed Google Scholar
Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormon-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895–7903, 1982 PubMed Google Scholar
Soubeyran I, Wafflart J, Bonichon F, DeMascarel I, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119–128, 1995 PubMed Google Scholar
Racca S, Conti G, Pietribiasi F, Stramignoni D, Tampellini M, Valetto MR, Ghezzo F, Di Carlo F: Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Int J Biol Markers 10: 87–93, 1995 PubMed Google Scholar
Foekens JA, Rio MC, Seguin P, VanPutten WL, Fauque J, Nap M, Klijn JG, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832–3837, 1990 PubMed Google Scholar
Horiguchi J, Lino Y, Takei H: Expression of pS2 estrogeninducible protein in primary breast cancer. Oncology 53: 12–15, 1996 PubMed Google Scholar
Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629–4636, 1981 PubMed Google Scholar
VanMourik JA, Lawrence DA, Loskutoff DJ: Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 259: 14914–14921, 1984 PubMed Google Scholar
Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64: 926–932, 1991 PubMed Google Scholar
Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195–208, 1993 PubMed Google Scholar
Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521, 1993 PubMed Google Scholar
Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A: Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res 63: 59–71, 1991 PubMed Google Scholar
Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S: Plasminogen activator system in human breast cancer. Int J Cancer 50: 345–348, 1992 PubMed Google Scholar
Tong D, Schneeberger C, Leodolter S, Zeillinger R: Quantitative determination of gene expression by competitive reverse transcription-polymerase chain reaction in degraded RNA samples. Anal Biochem 251: 173–177, 1997 PubMed Google Scholar
Kury FD, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Zeillinger R, Spona J: Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. Oncogene 5: 1403–1408, 1990 PubMed Google Scholar
Sedlák J, Sedláková O, Hlavcák P, Hunáková L, Bizik J, Grófová M, Chorváth B: Cell surface phenotype and increased penetration of human multidrug-resistant ovarian carcinoma cells into in vitro collagen-fibroblasts matrix. Neoplasma 43: 389–395, 1996 PubMed Google Scholar
Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534–544, 1992 PubMed Google Scholar
Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325–335, 1994 PubMed Google Scholar
Sliutz G, Eder H, Koelbl H, Tempfer C, Auerbach L, Schneeberger C, Kainz C, Zeillinger R: Quantification of uPA receptor expression in human breast cancer cell lines by cRTPCR. Breast Cancer Res Treat 40: 257–263, 1996 PubMed Google Scholar
Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO III: Effects of hormonereplacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336: 683–690, 1997 PubMed Google Scholar
Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH: Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 143: 159–166, 1996 PubMed Google Scholar
Dong G, Schulick AH, DeYoung MB, Dichek DA: Identi-fication of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-b1 responsiveness in endothelium in vivo. JBiol Chem 271: 29969–29977, 1996 Google Scholar
Keeton MR, Curriden SA, VanZonneveld AJ, Loskutoff DJ: Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor-beta. J Biol Chem 266: 23048–23052, 1991 PubMed Google Scholar
Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR: Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 75: 721–730, 1998 PubMed Google Scholar
Herman ME, Katzenellenbogen BS: Alterations in transforming growth factor-alpha and-beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867–5874, 1994 PubMed Google Scholar
Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor-beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 (Suppl 2): S15–S20, 1991 Google Scholar
Chen H, Tritton TR, Kenny N, Absher M, Chiu JF: Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61: 9–17, 1996 PubMed Google Scholar
Raymond WA, Leong AS: Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol 157: 299–306, 1989 PubMed Google Scholar
Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563–1571, 1996 PubMed Google Scholar
Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Hoist-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vacularization. Nat Med 4: 923–928, 1998 PubMed Google Scholar